Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PDE2A | O00408 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571556 | 0.86 | AR (0.51) | TDP1 | |
| SCHEMBL132042 | 0.84 | ALDH1A1 (0.41) | TDP1PDE2AALDH1A1AHRMEN1 | |
| SCHEMBL12402929 | 0.82 | PDE2A (0.40) | TDP1PDE2AMAPTALDH1A1AHR | |
| SCHEMBL29254639 | 0.82 | PDE2A (0.46) | PDE2AMAPTALDH1A1AHRBACE1 | |
| SCHEMBL6853258 | 0.81 | POLB (0.42) | TDP1MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL9996684 | 0.80 | PDE2A (0.44) | PDE2AMAPTALDH1A1AHRBACE1 | |
| SCHEMBL4057549 | 0.80 | TDP1 (0.55) | TDP1MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL9996686 | 0.80 | PDE2A (0.49) | PDE2AMAPTALDH1A1AHRBACE1 | |
| SCHEMBL1564067 | 0.78 | XBP1 (0.41) | TDP1MAPTPOLBALDH1A1MEN1 | |
| SCHEMBL875857 | 0.78 | POLB (0.50) | TDP1MAPTPOLBALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48335-E1 | Polymyxin derivatives as antimicrobial compounds | MONASH UNIVERSITY (AU) | 2020-12-01 | — | — | US | claimed |
| CN-106414480-B | Polymyxin derivatives as antimicrobial compounds | 莫纳什大学 | 2020-08-04 | — | — | CN | claimed |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2017-05-18 | — | — | US | claimed |
| EP-3126376-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | Monash University (AU) | 2017-02-08 | — | — | EP | claimed |
| WO-2015149131-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2015-10-08 | — | — | WO | claimed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| CN-119306679-A | Nitrogen-containing heterocyclic skeleton compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2025-01-14 | — | — | CN | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-12054484-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-0283173-A1 | Pesticidal method using 2-phenylimidazole derivatives | RHONE-POULENC AGRICULTURE LIMITED (GB) | 1988-09-21 | — | — | EP | disclosed |
| EP-0247320-A2 | 5-Arylalkyl-4-alkoxy-2(5H)-furanones, intermediates and process for their preparation as well as their application as therapeutically active ingredients | Dr. Willmar Schwabe GmbH & Co. (DE) | 1987-12-02 | — | — | EP | disclosed |
| US-4689068-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1987-08-25 | — | — | US | disclosed |
| EP-0191394-A1 | Isothioureas, process for their preparation and their use to combat undesirable plant growth | BASF Aktiengesellschaft (DE) | 1986-08-20 | — | — | EP | disclosed |
| US-4224340-A | Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds | WILLIAM H. RORER, INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4214003-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4197314-A | WITH A DIPHENYL NITRONE | WILLIAM H. RORER, INC. (US) | 1980-04-08 | — | — | US | disclosed |
| US-4153722-A | ANTIINFLAMMATORY, A-PHENYL-N-PHENYLNITRONE | WILLIAM H. RORER, INC. (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | TDP1 161/4885PDE2A 1640/4885MAPT 3947/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | TDP1 84/4885PDE2A 856/4885MAPT 2217/4885 |
| US-12054484-B2 | Substituted tetrahydropyrans as CCR2 modulators | CCR2, CCR1, CCR5 | TDP1 3313/4885PDE2A 2656/4885MAPT 3628/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | TDP1 84/4885PDE2A 856/4885MAPT 2217/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | TDP1 2538/4885PDE2A 1875/4885MAPT 2210/4885 |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | VIP, PEPD, NRDC | TDP1 4681/4885PDE2A 4201/4885MAPT 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.